On January 30th, in a landmark decision that could reshape the way acute pain is treated in the United States, the FDA approved suzetrigine (brand name, Journavx), a first-in-class non-opioid ...

Lastly, recent innovations in pain management, such as the FDA-approved Journavx™ (suzetrigine), will be discussed, offering a glimpse into the future of non-opioid therapies. By connecting ...

I'm especially bullish about another new drug in Vertex's lineup -- Journavx. In January, this drug became the first new class of pain medication approved by the FDA in over 20 years. Journavx ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...

Pain remains a complex, poorly understood experience, but the future is bright. Only last month, the FDA approved the use of a new medication Journavx for managing acute pain. It works by switching ...

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

My primary reason for optimism about Vertex over the near term is the launch of its new pain drug Journavx. The most important things to know about Journavx are: (1) it's effective at alleviating ...

That probably isn't an ancient Chinese curse as some think. However, many investors might wish that the times we live in weren't quite as interesting -- especially when it comes to the Nasdaq ...